# Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

> **NCT03697824** · PHASE2 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** GSK3377794
- **DRUG:** Pembrolizumab
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03697824
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-02-25
- **Primary completion:** 2022-07-18
- **Final completion:** 2022-07-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Internal decision, study will be replaced with a larger monotherapy trial
- **Last updated:** 2019-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03697824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03697824, "Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03697824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*